Type 2 diabetes mellitus (T2DM) is a major metabolic disease and one of the leading causes of death worldwide. The prevalence is on the rise, alongside increases in obesity due to lifestyle changes in the 21st century.
Type 2 diabetes is characterized by insulin resistance leading to dysregulation of glucose control and chronic hyperglycemia. This leads to several co-morbidities and complications, some of which are associated with damage to blood vessels as a result of elevated blood glucose levels.
The disease is progressive: patients’ standard of living deteriorate over time and the symptoms worsen, meaning more complex treatment regimens are required over time.
The complexity of the treatment means there is a high diversity of marketed products. In recent years new drug types have been great commercial successes and reached blockbuster status.
This alongside the financial cost of type 2 diabetes to healthcare providers has led to significant investment in R&D on therapeutics in this area.
Request a sample of this report @ orbisresearch.com/contacts/request-sample/2124082 .
- Requirement for new types of therapeutics to add to already complex treatment algorithms for severe T2DM
- What are the most important etiological risk factors and pathophysiological processes implicated in T2DM?
- What is the current treatment algorithm?
- How effective are current therapies for these indications, and how does this impact prognosis? What are the side effects associated with these treatments?
- The T2DM pipeline is dominated by G-protein-coupled receptors (GPCRs) and protein kinases
- Which molecule types and molecular targets are most prominent in the T2DM pipeline?
- Which first-in-class targets are most promising?
- How does the level of first-in-class innovation change within different target classes?
- How does first-in-class target diversity differ by stage of development and molecular target class?
- The deals landscape is active and dominated by products that target GPCRS and protein kinases
- Which molecular types/molecular target groups attract the highest deal values?
- How has deal activity fluctuated over the past decade?
- Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?
Browse the complete report @ orbisresearch.com/reports/index/fr…vascular-disease .
Reasons to access
- Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, and diagnosis and treatment options.
- Identify leading products and key unmet needs within the market.
- Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using proprietary matrix assessments, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential.
Individual matrix assessments are provided for targets identified in the pipeline for T2DM. Promising early-stage first-in-class targets are reviewed in greater detail.
- Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.
Access this report @ orbisresearch.com/contact/purchase/2124082 .
Some Points from Table of Content:
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Executive Summary 6
2.1 Competitive Market Landscape Driven by Rising Prevalence 6
2.2 Large and Diverse Pipeline Dominated by Products Acting on G Protein Coupled Receptors (GPCR) and Protein Kinases 6
2.3 Strong Opportunities for Investment in First-in-Class Products 6
3 The Case for Innovation 7
3.1 Growing Opportunities for Biologic Products 7
3.2 Diversification of Molecular Targets 8
3.3 Innovative First-in-Class Product Developments Remain Attractive 8
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Innovation 9
3.5 Sustained Innovation in Type 2 Diabetes Mellitus 9
4 Clinical and Commercial Landscape 10
4.1 Overview of Type 2 Diabetes Mellitus 10
4.2 Disease Classification 10
4.2.1 Type 1 Diabetes Mellitus 10
4.2.2 Type 2 Diabetes Mellitus 11
4.2.3 Type 3 Diabetes Mellitus 11
4.2.4 LADA 11
4.2.5 MODY 11
4.2.6 Gestational 11
4.2.7 Pancreatic diabetes 11
Category: Market Research Publishers and RetailersCompany about: Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have a vast database of reports from the leading publishers and authors across the gl obe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their need, and we produce the perfect requi ...